1,721,142 research outputs found
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia
No full textA 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia
Get PDFMenin inhibitors are new and promising agents currently in clinical development that target the HOX/MEIS1 transcriptional program which is critical for leukemogenesis in histone-lysine N-methyltransferase 2A-rearranged (KMT2Ar) and in NPM1-mutated (NPM1mut) acute leukemias. The mechanism of action of this new class of agents is based on the disruption of the menin–KMT2A complex (consisting of chromatin remodeling proteins), leading to the differentiation and apoptosis of AML cells expressing KMT2A or with mutated NPM1. To date, this new class of drugs has been tested in phase I and II clinical trials, both alone and in combination with synergistic drugs showing promising results in terms of response rates and safety in heavily pre-treated acute leukemia patients. In this brief review, we summarize the key findings on menin inhibitors, focusing on the mechanism of action and preliminary clinical data on the treatment of acute myeloid leukemia with this promising new class of agents, particularly revumenib and ziftomenib
Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years
Get PDFWe report on the feasibility and outcome of allogeneic SCT (allo-SCT) in 30 poor risk AML patients older than
60 years. Median age at transplant was 63 years (range 60-70 years) and 18/30 (60%) cases were in complete remission.
Donors were MUD in 40% and sibling in 60% of cases. Twenty-six of 30 patients (87%) received a reduced intensity
conditioning regimen (RIC). The hematopoietic cell transplantation specific comorbidity index (HCT-CI) was two or less
in 12/30 cases and three or more in 18/30 cases. All patients engrafted. One year Nonrelapse mortality (NRM) rate was
20% (6/30 cases). After a median follow-up of 16 months 17/30 patients (57%) were alive and in complete remission
while 13/30 (43%) have died (leukemia refractory or relapse 7/13 and NRM 6/13). Median Overall Survival for the whole
patient population was 28 months. The Overall Survival did not differ between unrelated and related donors. The patients
transplanted in complete remission had a significantly lower survival rate and relapse rate compared to those transplanted
with refractory or relapsed AML (P= 0.0004 and P= 0.008 respectively). The patients with a low HCT-CI (2 or less) had a
significantly lower NRM (P = 0.03) and survival rate (P = 0.02) compared to those with HCT-CI 3 or more.
Taking into account that this is a retrospective analysis with a small number of cases, these results confirm the feasibility
of allo-SCT for high risk AML patients older than 60 years. Outcome was significantly influenced by status of disease at
transplant and by HCT-CI. We also confirm that for older patients lacking a family donor MUD can provide a suitable
alternative option
Wilms' tumor 1 gene expression levels in acute promyelocytic leukemia compared to other acute myeloid leukemia subtypes
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with > 30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study
No full textDohner, H., Seymour, JF., Butrym, A., Wierzbowska, A., Selleslag, D., Lang, JH., Cavenagh, JD., Kumar, R., Schuh, Andre C., Candoni, Anna, Recher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Martinelli, Giovanni, Falantes, Jose, Stone, Richard M., Minden, Mark D., McIntyre, Heidi Songer, Stephen, Lucy, Lela M., Beach, C. L. Dombret, Herv
Clinical experience of antibodies to interferon-alpha during treatment of chronic myeloid leukemia
No full textInterferon-alpha (IFN-alpha) remains the only viable alternative to bone marrow transplantation for patients with chronic myeloid leukemia (CML) and is the treatment of choice in many circumstances. IFN-alpha can induce hematologic remissions in most patients with CML and suppresses the Philadelphia chromosome-positive cell clone in 30%-40% of hematologically responsive patients. IFN-alpha can also prolong the length of the chronic disease phase and survival time in patients who achieve a karyotypic response. A third of patients, however, never respond to IFN-alpha, and a proportion of the initial responders will later become resistant. It has been suggested that the induction of anti-IFN-alpha antibodies might be one of the reasons for resistance to IFN-alpha. It is difficult to evaluate the factors that influence antibody induction and the effects of these antibodies on clinical results. The source of IFN-alpha product, trial design, and differences in the sensitivity of the assays used to measure antibodies are all factors that need to be considered
- …
